F
Francesca Maria Quaglia
Researcher at University of Verona
Publications - 30
Citations - 583
Francesca Maria Quaglia is an academic researcher from University of Verona. The author has contributed to research in topics: Chronic lymphocytic leukemia & Medicine. The author has an hindex of 9, co-authored 21 publications receiving 270 citations. Previous affiliations of Francesca Maria Quaglia include University of Ferrara.
Papers
More filters
Journal ArticleDOI
COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus.
Lydia Scarfò,Thomas Chatzikonstantinou,Gian Matteo Rigolin,Giulia Quaresmini,Marina Motta,Candida Vitale,José A. García-Marco,Jose Angel Hernandez-Rivas,Fatima Miras,Mónica Baile,Juan Marquet,Carsten Utoft Niemann,Gianluigi Reda,Talha Munir,Eva Gimeno,Monia Marchetti,Francesca Maria Quaglia,Marzia Varettoni,Julio Delgado,Sunil Iyengar,Ann Janssens,Roberto Marasca,Angela Ferrari,Carolina Cuéllar-García,Gilad Itchaki,Martin Spacek,Lorenzo De Paoli,Luca Laurenti,Mark-David Levin,Enrico Lista,Francesca Romana Mauro,Martin Simkovic,Ellen van der Spek,Elisabeth Vandenberghe,Livio Trentin,Ewa Wasik-Szczepanek,Rosa Ruchlemer,Dominique Bron,Maria Rosaria De Paolis,Giovanni Del Poeta,Lucia Farina,Myriam Foglietta,Massimo Gentile,Yair Herishanu,Tobias Herold,Ozren Jakšić,Arnon P. Kater,Sabina Kersting,Lara Malerba,Lorella Orsucci,Viola Maria Popov,Paolo Sportoletti,Mohamed A. Yassin,Barbara Pocali,Gábor Barna,Annalisa Chiarenza,Gimena Dos Santos,Eugene Nikitin,Martin Andres,Maria Dimou,Michael Doubek,Alicia Enrico,Yervand K Hakobyan,Olga Kalashnikova,Macarena Ortiz Pareja,Maria Papaioannou,Davide Rossi,Nimish Shah,Amit Shrestha,Oana Stanca,Niki Stavroyianni,Vladimir Strugov,Constantine S. Tam,Mihnea Zdrenghea,Marta Coscia,Kostas Stamatopoulos,Giuseppe Rossi,Alessandro Rambaldi,Emili Montserrat,Robin Foà,Antonio Cuneo,Paolo Ghia +81 more
TL;DR: In CLL, COVID-19 severity increases with age; antileukemic treatment (particularly BTK inhibitors) appears to exert a protective effect; age and comorbidities did not impact on mortality, alluding to a relevant role of CLL and immunodeficiency.
Journal ArticleDOI
In CLL, comorbidities and the complex karyotype are associated with an inferior outcome independently of CLL-IPI.
Gian Matteo Rigolin,Maurizio Cavallari,Francesca Maria Quaglia,Luca Formigaro,Enrico Lista,Antonio Urso,Emanuele Guardalben,Carmine Liberatore,Danilo Faraci,Elena Saccenti,Cristian Bassi,Laura Lupini,Maria Antonella Bardi,Eleonora Volta,Elisa Tammiso,Aurora Melandri,Massimo Negrini,Francesco Cavazzini,Antonio Cuneo +18 more
TL;DR: The clinical course of the disease is quite heterogeneous with some patients living for years with asymptomatic disease and others experiencing early progression and requiring treatment with chemotherapy.
Journal ArticleDOI
Efficacy of R-BAC in relapsed, refractory mantle cell lymphoma post BTK inhibitor therapy.
Rory McCulloch,Carlo Visco,Toby A. Eyre,Rebecca Frewin,Neil Phillips,David L. Tucker,Francesca Maria Quaglia,Annabel McMillan,Jonathan Lambert,Nicola Crosbie,Simon Rule +10 more
TL;DR: R‐BAC demonstrates a high response rate in the post‐BTKi setting and in transplant eligible patients is an effective bridge to alloSCT.
Journal ArticleDOI
COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study.
Thomas Chatzikonstantinou,Anargyros Kapetanakis,Lydia Scarfò,Georgios Karakatsoulis,David Allsup,Alejandro Alonso Cabrero,Martin Andres,Darko Antic,Mónica Baile,Panagiotis Baliakas,Panagiotis Baliakas,Dominique Bron,Antonella Capasso,Sofia Chatzileontiadou,Raul Cordoba,Juan-Gonzalo Correa,Carolina Cuéllar-García,Lorenzo De Paoli,Maria Rosaria De Paolis,Giovanni Del Poeta,Christos Demosthenous,Maria Dimou,David Donaldson,Michael Doubek,Maria Efstathopoulou,Barbara Eichhorst,Shaimaa El-Ashwah,Alicia Enrico,Blanca Espinet,Lucia Farina,Angela Ferrari,Myriam Foglietta,Henrik Frederiksen,Moritz Fürstenau,José A. García-Marco,Rocío García-Serra,Massimo Gentile,Eva Gimeno,Andreas Glenthøj,Maria Gomes da Silva,Odit Gutwein,Yervand K Hakobyan,Yair Herishanu,Jose Angel Hernandez-Rivas,Tobias Herold,Idanna Innocenti,Gilad Itchaki,Ozren Jakšić,Ann Janssens,Оlga B Kalashnikova,Elżbieta Kalicińska,Linda Katharina Karlsson,Arnon P. Kater,Sabina Kersting,Jorge Labrador,Deepesh Lad,Luca Laurenti,Luca Laurenti,Mark-David Levin,Enrico Lista,Alberto Lopez-Garcia,Lara Malerba,Roberto Marasca,Monia Marchetti,Juan Marquet,Mattias Mattsson,Mattias Mattsson,Francesca Romana Mauro,Ivana Milosevic,Fatima Miras,Marta Morawska,Marta Morawska,Marina Motta,Talha Munir,Roberta Murru,Carsten Utoft Niemann,Raquel Nunes Rodrigues,Jacopo Olivieri,Lorella Orsucci,Maria Papaioannou,Miguel Arturo Pavlovsky,Inga Piskunova,Viola Maria Popov,Francesca Maria Quaglia,Giulia Quaresmini,Kristian Qvist,Gianluigi Reda,Gian Matteo Rigolin,Rosa Ruchlemer,Gevorg Saghumyan,Amit Shrestha,Martin Simkovic,Martin Spacek,Paolo Sportoletti,Oana Stanca,Niki Stavroyianni,Tamar Tadmor,Doreen te Raa,Sanne H. Tonino,Livio Trentin,Ellen van der Spek,Michel van Gelder,Roel van Kampen,Marzia Varettoni,Andrea Visentin,Candida Vitale,Ewa Wasik-Szczepanek,Tomasz Wróbel,Lucrecia Yáñez San Segundo,Mohamed A. Yassin,Marta Coscia,Alessandro Rambaldi,Emili Montserrat,Robin Foà,Antonio Cuneo,Kostas Stamatopoulos,Paolo Ghia +116 more
TL;DR: In this paper, the authors investigated the impact of CLL-directed treatments on the course of Coronavirus disease 2019 (COVID-19) and found that patients with chronic lymphocytic leukemia (CLL) may be more susceptible to the disease due to age, disease, and treatment-related immunosuppression.
Journal ArticleDOI
Outcomes in first relapsed-refractory younger patients with mantle cell lymphoma: results from the MANTLE-FIRST study.
Carlo Visco,Alice Di Rocco,Andrea Evangelista,Francesca Maria Quaglia,Maria Chiara Tisi,Lucia Morello,Vittorio Ruggero Zilioli,Chiara Rusconi,Stefan Hohaus,Roberta Sciarra,Alessandro Re,Cristina Tecchio,Annalisa Chiappella,Ana Marin-Niebla,Rory McCulloch,Guido Gini,Tommasina Perrone,Luca Nassi,Elsa Pennese,Piero Maria Stefani,Maria Christina Cox,Valentina Bozzoli,Alberto Fabbri,Valentina Polli,Simone Ferrero,Maria Isabel Alvarez De Celis,Antonello Sica,Luca Petrucci,Luca Arcaini,Simon Rule,Mauro Krampera,Umberto Vitolo,Monica Balzarotti +32 more
TL;DR: Ibrutinib was associated with improved outcome in early-POD patients, and rituximab-bendamustine-based treatments were balanced in terms of clinicopathological features.